Arcellx (ACLX) Stock Overview
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ACLX Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Arcellx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$114.39 |
| 52 Week High | US$114.80 |
| 52 Week Low | US$47.86 |
| Beta | 0.23 |
| 1 Month Change | 68.15% |
| 3 Month Change | 58.92% |
| 1 Year Change | 67.33% |
| 3 Year Change | 279.91% |
| 5 Year Change | n/a |
| Change since IPO | 580.89% |
Recent News & Updates
Recent updates
Arcellx: Funded Into 2028 With Strong Clinical Data
Dec 17Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results
Aug 10
We're Not Very Worried About Arcellx's (NASDAQ:ACLX) Cash Burn Rate
Jul 11We Think Arcellx (NASDAQ:ACLX) Can Easily Afford To Drive Business Growth
Apr 09Arcellx Impressive Safety Data Leaves Doubts
Mar 17Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy
Jan 16Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma
Sep 10Arcellx: Navigating The CAR T-Cell Revolution
Jan 30Shareholder Returns
| ACLX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | -1.2% | -1.5% |
| 1Y | 67.3% | 25.9% | 21.3% |
Return vs Industry: ACLX exceeded the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: ACLX exceeded the US Market which returned 21.3% over the past year.
Price Volatility
| ACLX volatility | |
|---|---|
| ACLX Average Weekly Movement | 23.1% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ACLX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ACLX's weekly volatility has increased from 13% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 209 | Rami Elghandour | www.arcellx.com |
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Arcellx, Inc. Fundamentals Summary
| ACLX fundamental statistics | |
|---|---|
| Market cap | US$6.72b |
| Earnings (TTM) | -US$228.93m |
| Revenue (TTM) | US$22.29m |
Is ACLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACLX income statement (TTM) | |
|---|---|
| Revenue | US$22.29m |
| Cost of Revenue | US$0 |
| Gross Profit | US$22.29m |
| Other Expenses | US$251.22m |
| Earnings | -US$228.93m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.90 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,027.25% |
| Debt/Equity Ratio | 0% |
How did ACLX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/10 21:30 |
| End of Day Share Price | 2026/03/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arcellx, Inc. is covered by 25 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| John Newman | Canaccord Genuity |